SITE007-0344

withdrawn

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2023-04-11

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-14 (study day 175); relationship: Y; serious criteria: hospitalization

moderate assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-10-18 (study day 179); relationship: not assessed

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-11-21 (study day 213); relationship: not assessed

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-07-12 (study day 447); relationship: not assessed

Data queries

No data queries.